Celldex: SNO 2015 (Celldex) - Dec 25, 2015 - “Mature randomized survival data continue to show a marked benefit (HR=0.53, p=0.0137) with long-term survival in this small trial; Long term survival not predicted by prognostic patient characteristics, Advantage to rindopepimut therapy across multiple endpoints including long-term progression-free survival, objective response rate and steroid requirement”; “The addition of rindopepimut to bevacizumab did not significantly increase toxicity: Associated with reduction in steroid usage”; “Remarkable frequency and level of anti-EGFRvIII immune responses despite prior chemotherapy and growing tumor: EGFRvIII antibody response correlates with potent effector function and improved clinical outcome”; “Activity profile consistent with prior immunotherapy experience”
P3 data • Biosimilar • Oncology
|